“Cancer has no geographic boundaries,” said Dr. Tolcher, CEO and founder of NEXT Oncology. “One of the continuing challenges has been that cancer research has been conducted in silos. Our goal has always been to break down those barriers and bring potentially life-saving therapies to people in other cities within Texas, while at the same time expediting the development of new …
Update on Conservative Management of the Axilla when the Sentinel Node is Positive in Breast cancer.
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Recently, there was an update on the AMAROS trial that now has 10-year results. In order to have perspective on this report, it is important to know that …
Oserdu FDA approval for Recurrent Metastatic Hormone Receptor Positive Breast cancer with ESR1 mutations
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Oserdu, an Oral SERD, was recently FDA approved for Recurrent Metastatic Hormone Receptor Positive Breast cancer with ESR1 mutations. What does this mean for women with breast cancer? …
Primary Results from the Randomized PHASE II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER 2 Neu- Advanced Brest Cancer Treated with Ribociclib Endocrine Therapy versus Treatment of Physicians Choice Combination Chemotherapy.
Presented at SABCS 2022 by Len-Shu Lu from the National Taiwan University Hospital, Taipei Taiwan. Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. The use of CDK4/6 inhibitors has emerged as a valuable treatment in the …
Evaluation of the Breast Cancer Index in Premenopausal women with Early Stage HR+ Breast Cancer in the Soft Trial.
Presented by Ruth O’ Regan et al. Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. This was a review of the tool called the Breast Cancer Index and its application for predicting the benefit of the …
ADCs in Breast Oncology: Present & Future
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Educational Symposium on ADCs @ December 2022 SABCS. Bioengineering & Mechanism of Action of Antibody Drug Conjugates (ADC) Presentation from Puja Sapra, PhD with SVP Biologics Engineering and …
Pregnancy Outcome & Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer.
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. POSITIVE TRIAL Pregnancy Outcome & Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer. (Initial Results from the POSITIVE Trial presented by Ann Partridge Harvard Medical …
A New Paradigm in Breast Cancer Treatment: Treating HER 2 NEU Low-Expressing Breast cancer
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. For years, breast cancer treatments have been influenced by the information obtained at the time of the original biopsy of the breast cancer. When someone is diagnosed with …
Pregnancy and Breast Cancer
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Recently, I attended two conferences about breast cancer, and both covered the special issue related to Pregnancy and Breast cancer. I think we are covering this issue more …
Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Clinical Trial. Chen, Si-Ye eta al.
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. How Long can you wait for Radiation after Surgery? Radiation treatment has remained an essential treatment particularly for those individuals who are at higher risk of breast cancer …